आर्मेनिया - अंग्रेज़ी - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd. - eptifibatide - solution for infusion - 0,75mg/ml

आर्मेनिया - अंग्रेज़ी - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd. - eptifibatide - solution for injection - 2mg/ml

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - eptifibatide - solution for infusion - 0.75 mg/ml

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - eptifibatide - solution for injection - 2 mg/ml

इसराइल - अंग्रेज़ी - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - solution for infusion - eptifibatide 0.75 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

इसराइल - अंग्रेज़ी - Ministry of Health

merck sharp & dohme (israel - 1996) company ltd, israel - eptifibatide - solution for injection - eptifibatide 2 mg/ml - eptifibatide - eptifibatide - integrilin is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. integrilin is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty, directional atheretomy, transluminal extraction catheter atherectomy, rotational ablation angioplasty, or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death, myorardial infarction, need for urgent intervention). integrilin is intended for use with aspirin and heparin.

इसराइल - अंग्रेज़ी - Ministry of Health

teva pharmaceutical indust.ltd - eptifibatide 2 mg/ml - solution for injection - eptifibatide - eptifibatide teva is indicated for the prevention of death and myocardial infarction in patients presenting with high risk unstable angina or non-q-wave myocardial infarction. eptifibatide is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. eptifibatide is also indicated as an adjunct to percutaneous transluminal coronary angioplasty (ptca) balloon angioplasty directional atheretomy transluminal extraction catheter atherectomy rotational ablation angioplasty or excimer laser angioplasty for the prevention of abrupt closure of the treated coronary vessel and related acute ischemic cardiac complications (death myorardial infarction need for urgent intervention). eptifibatide is intended for use with aspirin and heparin.

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - eptifibatide - injection - 2 mg/ml - eptifibatide 2 mg/ml

सिंगापुर - अंग्रेज़ी - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - eptifibatide - injection - 0.75 mg/ml - eptifibatide 0.75 mg/ml

कनाडा - अंग्रेज़ी - Health Canada

merck canada inc - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors